Researchers at the University of Oxford are developing OvarianVax, the first ovarian cancer vaccine aimed at preventing the disease that claims nearly 26,000 lives annually in the EU. Targeting women with genetic mutations, the vaccine seeks to train the immune system to detect early signs of ovarian cancer. If initial lab tests succeed, clinical trials will follow. The project is funded by Cancer Research UK, which emphasizes the potential for significant advancements in ovarian cancer survival. Article complet (Euronews.com)